| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | August 5, 2024 |
| Accession Number: | 0001193125-24-190814 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/8/2023 | $45.00 | Outperform → Market Perform | TD Cowen |
| 11/20/2023 | $25.00 | Neutral | JP Morgan |
| 9/28/2023 | $33.00 | Overweight | Piper Sandler |
| 8/3/2023 | $36.00 → $31.00 | Buy → Neutral | BofA Securities |
| 5/4/2023 | $30.00 | Equal Weight → Overweight | Wells Fargo |
| 4/10/2023 | Outperform | TD Cowen | |
| 3/17/2023 | $40.00 → $29.00 | Overweight → Neutral | JP Morgan |
| 3/16/2023 | $22.00 | Hold | Berenberg |
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
Cerevel's clinical-stage assets complement AbbVie's emerging neuroscience pipeline and leading on-market brands in psychiatry, migraine and Parkinson's diseaseEmraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophreniaCerevel is a strong strategic fit for AbbVie and has potential to meaningfully impact revenue into the next decadeAbbVie reaffirms previously issued 2024 full-year adjusted diluted EPS guidance range of $10.71-$10.91; reaffirms previously issued third-quarter adjusted diluted EPS guidance range of $2.92-$2.96NORTH CHICAGO, Ill., Aug. 1, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that it
NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- If you invested in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation or contacting us below. Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie. Under the terms of the transaction, AbbVie will acquire all outstanding shares of Cerevel for $45.00 per share in cash. The transaction values Cerevel at a total equity value of approximately $8.7 billion. The boards of directors of both companies have approved the transaction. This transaction is expected to clo
Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total "on" time without troublesome dyskinesia compared with placebo over 27 weeks Results demonstrate tavapadon's potential to provide the right balance of motor control, safety and tolerability for people living with Parkinson's disease Additional data from the trial will be presented at a future medical meeting; results from the tavapadon Phase 3 monotherapy trials (TEMPO-1 and TEMPO-2) are expected in the second half of 2024 CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unrav
SC 13D/A - Cerevel Therapeutics Holdings, Inc. (0001805387) (Subject)
SC 13D/A - Cerevel Therapeutics Holdings, Inc. (0001805387) (Subject)
SC 13G/A - Cerevel Therapeutics Holdings, Inc. (0001805387) (Subject)
TD Cowen downgraded Cerevel Therapeutics from Outperform to Market Perform and set a new price target of $45.00
JP Morgan resumed coverage of Cerevel Therapeutics with a rating of Neutral and set a new price target of $25.00
Piper Sandler initiated coverage of Cerevel Therapeutics with a rating of Overweight and set a new price target of $33.00
15-12G - Cerevel Therapeutics Holdings, Inc. (0001805387) (Filer)
EFFECT - Cerevel Therapeutics Holdings, Inc. (0001805387) (Filer)
EFFECT - Cerevel Therapeutics Holdings, Inc. (0001805387) (Filer)
Proposed acquisition adds robust pipeline of assets focused on best-in-class potential for psychiatric and neurological disorders where significant unmet needs remainCerevel's clinical-stage pipeline complements AbbVie's current on-market portfolio and emerging neuroscience pipelineEmraclidine has the potential to transform the standard of care in schizophrenia and other psychiatric conditionsTransaction valued at $45.00 per share in cash, for a total equity value of approximately $8.7 billionAbbVie to hold an investor conference call tomorrow, December 7, at 8:00 a.m. CTNORTH CHICAGO, Ill. and CAMBRIDGE, Mass., Dec. 6, 2023 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) and Cerevel Therapeutics (N
CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2023 financial results and business updates on Wednesday, November 1, 2023, before the U.S. financial markets open. Management will host a conference call to discuss third quarter financial results and business updates on Wednesday, November 1 at 8:00 a.m. ET. To access the call, please register at this link. Once registered, you will receive the dial-in information and a unique PIN number. A live webcast of the call, along with supporting slides, will be availabl
Three new executives added to leadership team: Ron Renaud, Susan Altschuller, Paul Burgess Emraclidine EMPOWER data now expected second half 2024 Darigabat ADAPT trial in panic disorder initiated Cash, cash equivalents, and marketable securities of $825.1 million as of June 30, 2023, expected to support a data-rich 2024 and fund operations into 2025 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the second quarter ended June 30, 2023 and provided key pipeline and business updat
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
Mr. Burgess will be responsible for leading Cerevel's business development and quality teams Mr. Burgess to join Cerevel effective June 20, 2023 CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Paul Burgess as chief business development and strategic operations officer, effective June 20, 2023. "I am so pleased to welcome Paul to Cerevel as our chief business development and strategic operations officer, with his proven track record of success in the biotech and pharmaceutical industry," said Ron Renaud, president and chie
Susan Altschuller, Ph.D. brings financial management, investor relations, and business planning experience from leading pharmaceutical and biotechnology companies to Cerevel Dr. Altschuller to become CFO effective May 15, 2023 CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Susan Altschuller, Ph.D. as chief financial officer (CFO), effective May 15, 2023. "We are excited to welcome Susan to Cerevel, as she brings a breadth of experience leading biopharmaceutical companies by leveraging her strategic understanding, f
CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Scott M. Akamine as chief legal officer, effective May 24, 2021. An accomplished legal executive, Mr. Akamine brings significant healthcare and biopharmaceutical experience to the role. He joins Cerevel from AEON Biopharma, Inc., a privately-held biopharmaceutical company, where he served as general counsel and corporate secretary, overseeing legal and certain administrative functions, including business development, corporate governance, intellectual property, and compliance.